Clinical Trial Update: Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation [Phase 2]

View source ↗

Summary

Enasidenib is being studied for relapsed or refractory IDH2-mutant acute myeloid leukemia in a Phase 2 trial. The study status is Active Not Recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• IDHIFA (enasidenib)

Snippet

Sponsor: Children's Oncology Group | Conditions: Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING